Logo image of UCB.BR

UCB SA (UCB.BR) Stock Price, Quote, News and Overview

EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR

169.7  +0.5 (+0.3%)

UCB.BR Quote, Performance and Key Statistics

UCB SA

EBR:UCB (5/5/2025, 7:00:00 PM)

169.7

+0.5 (+0.3%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High198.95
52 Week Low119.1
Market Cap33.01B
Shares194.51M
Float119.45M
Yearly Dividend1.36
Dividend Yield0.6%
PE34.08
Fwd PE22.88
Earnings (Next)07-23 2025-07-23
IPO01-02 1987-01-02


UCB.BR short term performance overview.The bars show the price performance of UCB.BR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

UCB.BR long term performance overview.The bars show the price performance of UCB.BR in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of UCB.BR is 169.7 EUR. In the past month the price increased by 4.3%. In the past year, price increased by 37.97%.

UCB SA / UCB Daily stock chart

UCB.BR Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 59.7 686.53B
LLY.DE ELI LILLY & CO 59.55 684.83B
ZEG.DE ASTRAZENECA PLC 19.54 394.99B
JNJ.DE JOHNSON & JOHNSON 15.45 329.34B
NOV.DE NOVO NORDISK A/S-B 20.23 272.07B
1SAN.MI SANOFI 14.56 239.91B
SNW.DE SANOFI 14.33 236.04B
SAN.PA SANOFI 14.26 235.01B
1MRKX.MI MERCK & CO. INC. 10.82 186.97B
6MK.DE MERCK & CO. INC. 10.57 182.69B
1PFE.MI PFIZER INC 7.48 120.06B
PFE.DE PFIZER INC 7.47 119.87B

About UCB.BR

Company Profile

UCB logo image UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Info

UCB SA

Allee de la Recherche, 60

Anderlecht BRUXELLES-CAPITALE BE

Employees: 9215

UCB Company Website

UCB Investor Relations

Phone: 3225599999

UCB SA / UCB.BR FAQ

What is the stock price of UCB SA today?

The current stock price of UCB.BR is 169.7 EUR. The price increased by 0.3% in the last trading session.


What is the ticker symbol for UCB SA stock?

The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.


On which exchange is UCB.BR stock listed?

UCB.BR stock is listed on the Euronext Brussels exchange.


What is the price forecast or stock price prediction for UCB SA stock?

25 analysts have analysed UCB.BR and the average price target is 211.54 EUR. This implies a price increase of 24.65% is expected in the next year compared to the current price of 169.7. Check the UCB SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UCB SA worth?

UCB SA (UCB.BR) has a market capitalization of 33.01B EUR. This makes UCB.BR a Large Cap stock.


How many employees does UCB SA have?

UCB SA (UCB.BR) currently has 9215 employees.


What are the support and resistance levels for UCB SA (UCB.BR) stock?

UCB SA (UCB.BR) has a support level at 137.16 and a resistance level at 169.71. Check the full technical report for a detailed analysis of UCB.BR support and resistance levels.


Is UCB SA (UCB.BR) expected to grow?

The Revenue of UCB SA (UCB.BR) is expected to grow by 16.61% in the next year. Check the estimates tab for more information on the UCB.BR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy UCB SA (UCB.BR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UCB SA (UCB.BR) stock pay dividends?

UCB SA (UCB.BR) has a dividend yield of 0.6%. The yearly dividend amount is currently 1.36. Check the full fundamental report for a detailed analysis of UCB.BR dividend history, reliability and sustainability.


When does UCB SA (UCB.BR) report earnings?

UCB SA (UCB.BR) will report earnings on 2025-07-23.


What is the Price/Earnings (PE) ratio of UCB SA (UCB.BR)?

The PE ratio for UCB SA (UCB.BR) is 34.08. This is based on the reported non-GAAP earnings per share of 4.98 and the current share price of 169.7 EUR. Check the full fundamental report for a full analysis of the valuation metrics for UCB.BR.


UCB.BR Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 88.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

UCB.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to UCB.BR. UCB.BR has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UCB.BR Financial Highlights

Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 4.98. The EPS increased by 18.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 17.31%
ROA 6.14%
ROE 10.62%
Debt/Equity 0.3
Chartmill High Growth Momentum
EPS Q2Q%84.08%
Sales Q2Q%26.21%
EPS 1Y (TTM)18.57%
Revenue 1Y (TTM)17.14%

UCB.BR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to UCB.BR. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of 48.96% and a revenue growth 16.61% for UCB.BR


Ownership
Inst Owners40.15%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts75.2
Price Target211.54 (24.66%)
EPS Next Y48.96%
Revenue Next Year16.61%